Ultrasonography in Children With First Febrile Urinary Tract Infection

Status Recruiting

Clinical Trial Summary

In recent decades, different tests have been recommended by guidelines in the management of first febrile urinary tract infection (fUTI) in children, including kidney ultrasound (KUS), cystography (VCUG) and renal scintigraphy in order to exclude underlying kidney anomalies. The majority of guidelines, continue to recommend a routine KUS for all children at the first fUTI. On the other hand, as this approach is not based on robust evidence, other guidelines suggest that KUS should only be performed on selected patients according to specific risks. Despite being a non-invasive and radiation-free method, KUS tests negative in 83% of cases of fUTIs and possesses low specificity for low grade vesico-ureteral reflux (VUR). Since VUR is the most commonly associated renal malformation with UTI, it is evident that all the guidelines focus on the research of VUR, especially in times when antenatal ultrasound allows to screen for major congenital anomalies of kidney and urinary tract (CAKUT). However, VUR-associated nephropathy appears to be related to primary dysplastic damage rather than to be secondary to the reflux itself and not preventable from antibiotic prophylaxis in terms of recurrence and of kidney scar. To reduce the number of normal VCUGs performed, recent evidence regarding VUR suggests that the presence of pathogens different from E. coli and UTI recurrence may help to identify children who necessitate further investigations. A preliminary retrospective monocentric study enrolling all patients aged 2 to 36 months diagnosed with first fUTI who subsequently underwent US evaluation of the kidneys and urinary tract, found that atypical germ and recurrence of UTI exhibits a 85% sensitivity to detect pathological ultrasound. The aim of this multicentric study is to prospectively evaluate the diagnostic accuracy of the presence of atypical germ combined with the recurrence of UTI in predicting the positivity of KUS in children aged 2 months to 3 years old with first episode of fUTI

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05814250
Study type	Observational
Source	IRCCS Burlo Garofolo
Contact	Marco Pennesi, MD
Phone	+39 040.3785.263
Email	marco.pennesi@burlo.trieste.it
Status	Recruiting
Phase
Start date	June 13, 2022
Completion date	March 31, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04495699` - Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
Terminated	`NCT05254808` - EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care	Phase 3
Completed	`NCT03680612` - Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI	Phase 2
Completed	`NCT03282006` - Treating Pyelonephritis an Urosepsis With Pivmecillinam	Phase 4
Completed	`NCT03526484` - The Utility of Urinalysis Prior to In-Office Procedures	N/A
Completed	`NCT05397782` - Effects of Flourish on Recurrent Urinary Tract Infection	N/A
Completed	`NCT05018546` - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery	N/A
Completed	`NCT03687255` - Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections	Phase 3
Recruiting	`NCT05227937` - Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
Completed	`NCT02864420` - Hospitalization at Home: The Acute Care Home Hospital Program for Adults	N/A
Completed	`NCT03131609` - Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
Completed	`NCT01911143` - A Retrospective, Blinded Validation of a Host-response Based Diagnostics	N/A
Completed	`NCT01333254` - A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients	N/A
Terminated	`NCT00594594` - Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury	Phase 1
Completed	`NCT00216853` - A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection	N/A
Completed	`NCT00787085` - The Significance of Funguria in Hospitalized Patients	N/A
Completed	`NCT05719753` - The Effectiveness of a Bacteriophobic Coating on Urinary Catheters	N/A
Recruiting	`NCT05415865` - The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder	Phase 3
Not yet recruiting	`NCT05880329` - DIagnoSing Care hOme UTI Study
Recruiting	`NCT04615065` - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.